Orange Health Labs Crossed ₹180 Crore ARR as India’s Diagnostics Sector Shifted Toward Consumer First Healthcare

Orange Health Labs reported strong FY26 growth with ₹138 crore in revenue and a ₹180 crore annual recurring revenue run rate, highlighting rising investor confidence and growing consumer demand for faster, technology driven diagnostic services in India’s evolving healthcare ecosystem.

India’s diagnostics industry has traditionally been associated with long waiting periods, fragmented service quality, and inconsistent customer experiences. But over the last few years, a new generation of health technology startups has attempted to transform the sector by positioning diagnostics as a consumer centric, technology enabled, and convenience driven service.

Among the companies leading that transition has been Orange Health Labs, which announced strong financial and operational growth for FY26, reporting ₹138 crore in revenue while exiting the year at an annual recurring revenue run rate of ₹180 crore.

The Bengaluru headquartered company stated that both its last twelve month revenue and ARR grew 65 percent year on year, marking its third consecutive year of sustained high growth. With more than three million orders served to date, the company has continued to strengthen its position within India’s rapidly expanding diagnostics and preventive healthcare segment.

The growth comes amid rising consumer awareness around preventive health monitoring, digital healthcare adoption, and demand for faster at home medical services across urban India.

Founded with a focus on speed led diagnostics, Orange Health Labs built its market identity around rapid sample collection and accelerated report delivery timelines. The company claimed it consistently maintained more than 99 percent on time sample collection rates, reinforcing operational reliability as a key differentiator in a highly competitive healthcare market.

Over the last year, the company significantly expanded its physical and digital footprint across Bengaluru, Mumbai, Delhi NCR, and Hyderabad. It also scaled its retail presence aggressively, increasing its network from 15 stores to more than 75 company owned collection centres, including nearly 50 centres in Bengaluru alone.

Unlike traditional pathology chains that relied heavily on centralised physical labs and walk in testing, Orange Health Labs positioned itself around a hybrid healthcare delivery model that integrated at home diagnostics with omnichannel retail accessibility.

The company also reported an important profitability milestone. It achieved 20 percent EBITDA profitability in Bengaluru while becoming operationally profitable across all active cities, a development that industry analysts viewed as particularly significant in India’s consumer health startup ecosystem where growth has often outpaced sustainable economics.

Commenting on the milestone, Dhruv Gupta, Co founder of Orange Health Labs, stated that the year represented an important inflection point for the business, particularly as strong growth coincided with improving profitability metrics.

He noted that the company’s core strategy had remained focused on building the fastest and most reliable diagnostics experience in the market, adding that sustained consumer trust had become a critical driver of growth in a category where reliability and transparency directly influence long term adoption.

Alongside operational expansion, the company also invested heavily in digital healthcare tools aimed at improving patient engagement and long term health management.

One such innovation was NeO Reports, a platform designed to simplify the way consumers viewed, filtered, organised, and shared diagnostic results with family members and healthcare providers. The company also launched Orange One, which it described as India’s first annual diagnostics membership plan designed to move consumers away from episodic testing toward proactive and continuous health monitoring.

According to Tarun Bhambra, the broader objective was to reposition diagnostics from a reactive healthcare activity into an integrated real time health management service.

He emphasised that speed and operational efficiency alone were no longer sufficient differentiators in the evolving healthcare market. Instead, the future of diagnostics would increasingly depend on transparency, digital integration, accessibility, and personalised healthcare experiences.

Beyond consumer diagnostics, Orange Health Labs also continued strengthening its healthcare ecosystem partnerships. The company onboarded more than 2,000 clinics onto its proprietary platform, enabling doctors to access faster testing workflows and improved clinical decision making support.

Investor confidence in the business also remained strong. The company has raised approximately $50 million to date from prominent global investors including Y Combinator, Accel, General Catalyst, Bertelsmann India Investments, and Amazon Sambhav Venture Fund.

As India’s healthcare sector increasingly shifted toward digitally enabled, consumer focused service models, companies such as Orange Health Labs illustrated how diagnostics was evolving from a backend healthcare utility into a technology driven consumer experience category.

In a market where trust, speed, and convenience were becoming central to healthcare decisions, the company’s growth trajectory reflected a larger transformation underway across India’s preventive health and digital diagnostics landscape.